Sequus regulatory update

SEQU's long-circulating Stealth liposome formulation of doxorubicin received unanimous opinion from the European Committee on Proprietary and Medicinal Products (CPMP) for approval as an anticancer treatment. The CPMP recommended use of the drug for both first-line and second-line treatment of AIDS-related Kaposi's sarcoma in patients with low CD4 counts and extensive mucocutaneous or visceral disease. The drug, marketed as Doxil in the U.S., will be sold under the trade name Caelyx in Europe. ...